AbCellera Biologics (ABCL) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $68.8 million.

  • AbCellera Biologics' Total Current Liabilities fell 1352.81% to $68.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.8 million, marking a year-over-year decrease of 1352.81%. This contributed to the annual value of $76.6 million for FY2024, which is 3562.72% down from last year.
  • AbCellera Biologics' Total Current Liabilities amounted to $68.8 million in Q3 2025, which was down 1352.81% from $67.0 million recorded in Q2 2025.
  • AbCellera Biologics' 5-year Total Current Liabilities high stood at $221.1 million for Q2 2022, and its period low was $49.5 million during Q3 2021.
  • Moreover, its 5-year median value for Total Current Liabilities was $89.6 million (2023), whereas its average is $103.6 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first soared by 21701.02% in 2022, then plummeted by 5802.09% in 2023.
  • Over the past 5 years, AbCellera Biologics' Total Current Liabilities (Quarter) stood at $120.7 million in 2021, then dropped by 1.95% to $118.3 million in 2022, then grew by 0.59% to $119.0 million in 2023, then plummeted by 35.63% to $76.6 million in 2024, then dropped by 10.19% to $68.8 million in 2025.
  • Its Total Current Liabilities was $68.8 million in Q3 2025, compared to $67.0 million in Q2 2025 and $75.4 million in Q1 2025.